Tourette syndrome: A case for noradrenergic and opiatergic mechanisms

References

• Aghajanian G. K. Central noradrenergic neurons: A locus for the functional interplay between alpha-2 adrenoreceptors and opiate receptors. Journal of Clinical Psychiatry 1982; 43(6, Sec. 2)20–24
   PubMed Web of Science ®Google Scholar
• Bercez J. M., Dysken M. W., Davis J. M. Naloxone effect in Tourette syndrome. Neurology 1979; 29: 1316–1317
   PubMed Web of Science ®Google Scholar
• Berkowitz B. A., Ngai S. H., Finck A. D. Nitrous oxide analgesia: Resemblance to opiate action. Science 1976; 194: 967–974
   PubMed Web of Science ®Google Scholar
• Blum I., Munitz H., Shalev A., Roberts E. Naloxone may be beneficial in the treatment of tardive dyskinesia. Clinical Neuropharmacology 1986; 7: 265–267
   Web of Science ®Google Scholar
• Butler I. J., Koslow S., Seifert W. Biogenic amine metabolism in Tourette syndrome. Annals of Neurology 1982; 6: 37–39
   Google Scholar
• Cohen D. J., Detlor J., Young J. G. Clonidine ameliorates Gilles de la Tourette syndrome. Archives of General Psychiatry 1980; 37: 1350–1357
   PubMed Web of Science ®Google Scholar
• Creese I., Feinberg A. P., Snyder S. H. Butyrophenone influences on the opiate receptor. European Journal of Pharmacology 1976; 36: 231–236
   PubMed Web of Science ®Google Scholar
• Cuello A. C. Central distribution of opioid peptides. British Medical Bulletin 1983; 39: 11–16
   PubMed Web of Science ®Google Scholar
• Dorsey R. Clonidine and Gilles de la Tourette syndrome. Archives of General Psychiatry 1981; 38: 1185
   PubMed Web of Science ®Google Scholar
• Dysken M. W., Berecz J. M., Samareza A. Clonidine in Tourette syndrome. Lancet 1980; 2: 916–917
   PubMed Web of Science ®Google Scholar
• Emricb H. M., Cording C., Piree S. Indication of an antipsychotic action of an opiate antagonist naloxone. Pharmakopsychiatry 1977; 10: 265–270
   Google Scholar
• Farsang C., Kunos G. Naloxone reverses the antihypertensive effect of clonidine. British Journal of Pharmacology 1979; 67: 161–164
   PubMed Web of Science ®Google Scholar
• Gillman M. A., Sandyk R. Tourette syndrome: Effect of analgesic concentrations of nitrous oxide and naloxone. British Medical Journal 1984; 288: 114
   PubMedGoogle Scholar
• Gillman M. A., Sandyk R. Tourette syndrome and the opioid system. Psychiatry Research 1985b; 15: 161–162
   PubMed Web of Science ®Google Scholar
• Gillman M. A., Sandyk R., Lichtigfeld F. J. Evidence for underactivity of the opioid system in neuroleptic-induced akathisia. Psychiatry Research 1984; 13: 187
   PubMed Web of Science ®Google Scholar
• Glassman A. H., Jackson W. K., Walsh B. T., Roose S. P., Rosenfeld B. Cigarette craving, smoking, withdrawal, and clonidine. Science 1984; 226: 864–866
   PubMed Web of Science ®Google Scholar
• Goldstein J. A. Nifedipine treatment of Tourette's syndrome. Journal of Clinical Psychiatry 1984; 45: 360
   PubMed Web of Science ®Google Scholar
• Gounce M., Barbeau A. Several cases of Gilles de la Tourette syndrome: Partial relief with clonazepam. A pilot study. Canadian Journal of Neurological Science 1977; 4: 279–283
   PubMedGoogle Scholar
• Gunne L. M., Lindstrom L., Terenivs L. Naloxone-induced reversal of schizophrenic hallucinations. Journal of Neural Transmission 1977; 40: 13–19
   PubMed Web of Science ®Google Scholar
• Hong J. S., Yang H. Y. T., Gillin J. C. Chronic treatment with haloperidol accelerates the biosynthesis of encephalins in rat striatum. Brain Research 1979; 160: 192–195
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O. Brain catecholamine in schizophrenia—a good case for noradrenaline. Nature 1982; 299: 484–485
   PubMed Web of Science ®Google Scholar
• Insel T. R., Pickar D. Naloxone administration in obsessive-compulsive disorder. Report of 2 cases. American Journal of Psychiatry 1983; 140: 1219–1220
   PubMed Web of Science ®Google Scholar
• Jankovic J., Glaze D. F., Frost J. D. Reply from the authors. Neurology 1985; 35: 450
   Google Scholar
• Lal H. Narcotic dependence, narcotic action and dopamine receptors. Life Sciences 1980; 17: 483–496
   Google Scholar
• Leckman J. F., Cohen D. J. Recent advances in Gilles de la Tourette syndrome. Implications for clinical practice and future research. Psychiatric Developments 1983; 3: 301–316
   Google Scholar
• Leckman J. F., Cohen D. J., Detlor J. Clonidine in the treatment of Tourette syndrome: A review of data. Advances in Neurology 1979; 35: 391–401
   Google Scholar
• Messiha F. S., Erickson H. M., Goggin J. E. Lithium carbonate in Gilles de la Tourette's disease. Research Communications in Chemistry, Pathology, Pharmacology 1976; 15: 609–613
   PubMedGoogle Scholar
• Monti J. M. Noradrenergic modulation of REM sleep: Pharmacological evidence. Trends in Pharmacological Science 1983; 4: 133–135
   Web of Science ®Google Scholar
• Pepper C. M., Henderson G. Opiates and opioid peptide hyperpolarize locus coeruleus neurons. in vitro. Science 1980; 209: 394–396
   Google Scholar
• Pettibone D. J., Mueller G. P. Clonidine releases immunoreactive beta-endorphin from rat pars distalis. Brain Research 1981; 221: 409–414
   PubMed Web of Science ®Google Scholar
• Pycock C. J., Burns S., Morris R. In vitro release of serotonin and GABA from rat periaqueductal grey and raphe dorsalis region produced by morphine or an enkephalin analogue. Neuroscience Letters 1981; 22: 313–317
   Web of Science ®Google Scholar
• Redmond D. E., Huang Y. H. The primate locus coeruleus and effects of clonidine on opiate withdrawal. Journal of Clinical Psychiatry 1982; 43(Sec. 2)25–29
   PubMedGoogle Scholar
• Sandyk R. Naloxone withdrawal exacerbates Tourette's syndrome. Journal of Clinical Psycho-pharmacology 1986f; 6: 58–59
   PubMed Web of Science ®Google Scholar
• Sandyk R. Endogenous opioid system in catatonia. Psychiatry Research 1985c; 15: 159
   PubMed Web of Science ®Google Scholar
• Sandyk R. Naloxone ameliorates narcolepsy. Clinical Neuropharmacology 1985d; 8: 96–97
   PubMed Web of Science ®Google Scholar
• Sandyk R. The effect of naloxone in Tourette's syndrome. Annals of Neurology 1985e; 18: 367–368
   PubMed Web of Science ®Google Scholar
• Sandyk R. The opioid-noradrenergic link in Gilles de la Tourette's syndrome. Clinical Pharmacy 1985b; 4: 494
   PubMedGoogle Scholar
• Sandyk R. The endogenous opioid system in disorders of the basal-ganglia. Life Sciences 1985a; 37: 1655–1663
   PubMed Web of Science ®Google Scholar
• Sandyk R. Autoaddiction and autowithdrawal phenomena in Tourette's syndrome. Journal of Autism and Developmental Disorders, in press
   Google Scholar
• Sandyk R. Tourette's syndrome: Successful treatment with clonidine and oxycodone. Journal of Neurology, in press
   Web of Science ®Google Scholar
• Sandyk R., Gillman M. A. Naloxone does not benefit levodopa-induced hallucinations in Parkinson's disease. Annals of Neurology 1984a; 16: 723
   PubMed Web of Science ®Google Scholar
• Sandyk R., Snider S. R. Naloxone and tardive dyskinesia. Biological Psychiatry 1985i; 20: 1335–1336
   PubMed Web of Science ®Google Scholar
• Sandyk R., Snider S. R. Sensory symptoms in Parkinson's disease. Neurology 1985j; 35: 619–620
   PubMed Web of Science ®Google Scholar
• Sandyk R., Snider S. R. Naloxone ameliorates levodopa-induced dyskinesias in Parkinson's disease. American Journal of Psychiatry 1986; 143: 118
   PubMed Web of Science ®Google Scholar
• Schwartz J. C. Opiate receptors on catecholamine neurons in brain. Trends in Neurological Sciences 1979; 2: 137–139
   Web of Science ®Google Scholar
• Seeger T. F., Nazzaro J. M., Gardner E. L. Selective inhibition of mesolimbic behavioral supersensitivity by naloxone. European Journal of Pharmacology 1980; 65: 435–438
   PubMed Web of Science ®Google Scholar
• Shapiro A. K., Shapiro E., Wayne H. L. The symptomatology and diagnosis of Gilles de la Tourette syndrome. Journal American Academy of Child Psychiatry 1973; 12: 702–723
   PubMedGoogle Scholar
• Shapiro A. K., Shapiro E., Eisenkraft G. J. Treatment of Gilles de la Tourette syndrome with clonidine and neuroleptics. Archives General Psychiatry 1983; 40: 1235–1240
   PubMed Web of Science ®Google Scholar
• Strake K., Montel H. Involvement of alpha-adrenoreceptor in clonidine-induced inhibition of transmitter release from central monamine neurones. Neuropharmacology 1973; 12: 1073–1081
   PubMed Web of Science ®Google Scholar
• Tassin J. P., Simon H., Herve D. Non dopaminergic fibres may regulate dopamine-sensitive adenylate cyclase in the prefrontal cortex and nucleus accumbens. Nature 1982; 295: 696–698
   PubMed Web of Science ®Google Scholar
• Trabulchi M., Bass S., Frattola L. Effect of naloxone on the “On-Off” syndrone in patients receiving long-term levodopa therapy. Archives of Neurology 1982; 39: 120–121
   PubMedGoogle Scholar
• Watson S. J., Akil H., Berger P. A., Barchas J. D. Some observations on the opiate peptides and schizophrenia. Archives General Psychiatry 1979; 36: 35–41
   PubMed Web of Science ®Google Scholar
• Young J. G., Cohen D. J., Hattox S. E. Plasma free MHPG and neuroendocrine response to challenge doses of clonidine in Tourette syndrome: Preliminary report. Life Sciences 1981; 29: 1467–1475
   PubMed Web of Science ®Google Scholar